Gurgaon, India, April 25, 2011

Ranbaxy Laboratories Limited (Ranbaxy) today announced the Day-1 launch of Olanzapine Tablets, the generic version of Zyprexa. Ranbaxy will be introducing Olanzapine tablets 2.5mg, 5mg, 7.5mg and 10mg and also orodispersables in 5mg and 10mg. Zyprexa is the innovator product of Eli Lilly and has a market size of $ 210 million (Source: 2010 IMS Data).

Ranbaxy has received necessary regulatory approvals from the Spanish Health Authorities  to manufacture and market Olanzapine in Spain and will be launching the product on Day-1, following patent expiry.

Commenting on the Day-1 launch, Ranbaxy's Country Manager in Spain, Pere-Lluís Sala,  said, "Ranbaxy has a strong portfolio of CNS products and the launch of Olanzapine further deepens our offering in this space. Ranbaxy will be promoting its generic Olanzapine through Physicians and Pharmacies with immediate effect. The Generic alternative will bring about significant savings for Patients and the Spanish Health System which has been encouraging generic prescription as a means to make healthcare, affordable."

Olanzapine  is an atypical antipsychotic, and is indicated for the treatment of schizophrenia in adults. The product is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial positive response. Olanzapine is also indicated for the treatment of moderate to severe manic episodes and prevents their recurrence. It is also indicated for the treatment of Bipolar disorders.

Ranbaxy Spain established operations in the country in 2004 and today offers a wide array of pharmaceutical products  that cover therapy areas such as Gastrointestinals, Cardiovascular, CNS and Antibiotics. The company plans to add significantly to this product range during the year.

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals, in developed and emerging markets many of which incorporate proprietary Novel Drug Delivery Systems (NDDS) and technologies, developed at its own labs. The company has further strengthened its focus on generics research and is increasingly working on more complex and specialty areas. Ranbaxy serves its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 46 countries and manufacturing operations in 7 countries. Ranbaxy is a member of the Daiichi Sankyo Group. Through strategic in-licensing opportunities and  its hybrid business model with Daiichi Sankyo, a leading global pharma innovator headquartered in Tokyo, Japan, Ranbaxy is introducing many innovator products in markets around the world, where it has a strong presence. This is in line with the company's commitment to increase penetration and improve access to medicines, across the globe.

Suggested Articles

The NIH is starting with Eli Lilly and AbCellera's COVID-19 antibody but could add more prospects as the trial goes on.

The series B positions ex-AveXis executives to build a biotech with a broad gene therapy pipeline and infrastructure to match.

A variant of the ACE2 receptor could work as a COVID-19 therapeutic by drawing the virus away from healthy cells, scientists reported.